Related references
Note: Only part of the references are listed.Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir
Nicholas A. Meanwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Prodrug strategy for cancer cell-specific targeting: A recent overview
Xian Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Braeuer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Prodrugs - Recent approvals and a glimpse of the pipeline
Jarkko Rautio et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Immunotherapy for head and neck cancer: the future of treatment?
Xiujie Xie et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Reaction phenotyping to assess victim drug-drug interaction risks
Li Di
EXPERT OPINION ON DRUG DISCOVERY (2017)
In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey
Patrick E. Trapa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Dimitri E. Grigoriadis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Recent advances in macromolecular prodrugs
Camilla Frich Riber et al.
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE (2017)
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Jadwiga Najib et al.
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2017)
Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations
Surinder K. Sharma et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives
Anna Scomparin et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Lesley J. Scott
DRUGS (2017)
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors
Gabriel Birkus et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors
X. Wang et al.
PHARMACOGENOMICS JOURNAL (2016)
A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children
V. Lukacova et al.
AAPS JOURNAL (2016)
Proteases in cancer drug delivery
Jennifer Vandooren et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
Adrian S. Ray et al.
ANTIVIRAL RESEARCH (2016)
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2016)
Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space
Nicholas A. Meanwell
CHEMICAL RESEARCH IN TOXICOLOGY (2016)
Lisdexamfetamine: A pharmacokinetic review
Eloisa Comiran et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
The codrug approach for facilitating drug delivery and bioactivity
Ibrahim A. Aljuffali et al.
EXPERT OPINION ON DRUG DELIVERY (2016)
Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates
Peter J. Thornton et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery
N. Gobeau et al.
PHARMACEUTICAL RESEARCH (2016)
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Ralf A. Linker et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Giancarlo A. Garcia et al.
CLINICAL OPHTHALMOLOGY (2016)
ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF FUNGAL INFECTION
R. C. Walker et al.
DRUGS OF TODAY (2016)
Antibody-Drug Conjugates for Cancer Therapy
Adam C. Parslow et al.
BIOMEDICINES (2016)
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
Jessica R. McCombs et al.
AAPS JOURNAL (2015)
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
Brian J. Kirby et al.
CLINICAL PHARMACOKINETICS (2015)
Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension
Sheridan M. Hoy
DRUGS (2015)
Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies
Jef Stappaerts et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Tetsuo Asaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
Giulio Casi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes
Hao Xu et al.
MOLECULAR PHARMACEUTICS (2015)
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
Christopher F. O'Brien et al.
MOVEMENT DISORDERS (2015)
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Madduri Srinivasarao et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Gene-Directed Enzyme Prodrug Therapy
Jin Zhang et al.
AAPS JOURNAL (2015)
Quantitative Assessment of Intestinal First-pass Metabolism of Oral Drugs Using Portal-vein Cannulated Rats
Yoshiki Matsuda et al.
PHARMACEUTICAL RESEARCH (2015)
Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
Luciano Quaranta et al.
CLINICAL OPHTHALMOLOGY (2015)
Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics
Nassim Djebli et al.
DRUG METABOLISM AND DISPOSITION (2015)
Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs
Ugo Pradere et al.
CHEMICAL REVIEWS (2014)
Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition
Zhe-Yi Hu et al.
CLINICAL PHARMACOKINETICS (2014)
Chemistry-enabled drug delivery (prodrugs): recent progress and challenges
Sophie-Dorothee Clas et al.
DRUG DISCOVERY TODAY (2014)
Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery
Peter Timmins et al.
DRUG DISCOVERY TODAY (2014)
Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
Magdalena Slusarczyk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects
Shirin Bruderer et al.
PHARMACOLOGY (2014)
Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro-In Vivo Extrapolation of Clearance of Prodrugs
Haruka Nishimuta et al.
DRUG METABOLISM AND DISPOSITION (2014)
Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis
S. Casey Laizure et al.
DRUG METABOLISM AND DISPOSITION (2014)
Polymer therapeutics-prospects for 21st century: The end of the beginning
Ruth Duncan et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Amino acids as promoieties in prodrug design and development
Balvinder S. Vig et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer
Christopher R. Garrett et al.
CANCER (2013)
Drug transport via the intestinal peptide transporter PepT1
Matthias Brandsch
CURRENT OPINION IN PHARMACOLOGY (2013)
Cytochrome P450-activated prodrugs
Paul R Ortiz de Montellano
Future Medicinal Chemistry (2013)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Population Pharmacokinetics and Pharmacodynamics of Gabapentin After Administration of Gabapentin Enacarbil
Ritu Lal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug
Jonathan Brown et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
S. Casey Laizure et al.
PHARMACOTHERAPY (2013)
Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach
Jonas Malmborg et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2013)
The discovery of dabigatran etexilate
Joanne van Ryn et al.
FRONTIERS IN PHARMACOLOGY (2013)
Glutathione Transferase (GST)-Activated Prodrugs
Paolo Ruzza et al.
Pharmaceutics (2013)
Strategies to Address Low Drug Solubility in Discovery and Development
Hywel D. Williams et al.
PHARMACOLOGICAL REVIEWS (2013)
Activation of Benznidazole by Trypanosomal Type I Nitroreductases Results in Glyoxal Formation
Belinda S. Hall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms
Jonathan R. Fromm et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Evidence-based approach to assess passive diffusion and carrier-mediated drug transport
Li Di et al.
DRUG DISCOVERY TODAY (2012)
Bridging solubility between drug discovery and development
Li Di et al.
DRUG DISCOVERY TODAY (2012)
Dabigatran Etexilate A Review of its Use for the Prevention of Venous Thromboembolism after Total Hip or Knee Replacement Surgery
Celeste B. Burness et al.
DRUGS (2012)
Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects
Richard E. Nettles et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)
John F. Kadow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: A case study example with the prodrug ceftobiprole medocaril
Gary Eichenbaum et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Species difference of esterase expression and hydrolase activity in plasma
Fatma Goksin Bahar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Theodore W. Kurtz et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2012)
A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair
Grace Zhixia Yan et al.
DRUG METABOLISM AND DISPOSITION (2012)
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Shashwat S. Banerjee et al.
JOURNAL OF DRUG DELIVERY (2012)
Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661
Phillip A. Furman et al.
ANTIVIRAL RESEARCH (2011)
Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety
Nicholas A. Meanwell
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
Polymer therapeutics as nanomedicines: new perspectives
Ruth Duncan
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Shane R. Wilkinson et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Rational Design and Development of Colon-Specific Prodrugs
Suneela S. Dhaneshwar et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human
Eric T. Williams et al.
DRUG METABOLISM AND DISPOSITION (2011)
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma
Karen M. VanderMolen et al.
JOURNAL OF ANTIBIOTICS (2011)
CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
Boon Shing Tan et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Nanomedicine(s) under the Microscope
Ruth Duncan et al.
MOLECULAR PHARMACEUTICS (2011)
Prodrugs-from Serendipity to Rational Design
Kristiina M. Huttunen et al.
PHARMACOLOGICAL REVIEWS (2011)
Enzyme-mediated hydrolytic activation of prodrugs
Yan-hui Yang et al.
ACTA PHARMACEUTICA SINICA B (2011)
PSI-7851, a Pronucleotide of β-D-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
Angela M. Lam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The Role of Intestinal Carboxylesterase in the Oral Absorption of Prodrugs
Teruko Imai et al.
CURRENT DRUG METABOLISM (2010)
Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists
S. Jana et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
Eisuke Murakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Discovery of a β-D-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
Michael J. Sofia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Prodrugs: Some Thoughts and Current Issues
Valentino J. Stella
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Coexistence of passive and carrier-mediated processes in drug transport
Kiyohiko Sugano et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
ESLICARBAZEPINE ACETATE: A WELL-KEPT SECRET?
Elinor Ben-Menachem
EPILEPSY CURRENTS (2010)
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick
Neuropsychiatric Disease and Treatment (2010)
Population-Based Mechanistic Prediction of Oral Drug Absorption
Masoud Jamei et al.
AAPS JOURNAL (2009)
Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells
Youcef Mehellou et al.
CHEMMEDCHEM (2009)
Pharmacokinetics and Tolerability of Single Escalating Doses of Gabapentin Enacarbil: A Randomized-Sequence, Double-Blind, Placebo-Controlled Crossover Study in Healthy Volunteers
Ritu Lal et al.
CLINICAL THERAPEUTICS (2009)
Evaluation of in Vitro Models for Screening Alkaline Phosphatase-Mediated Bioconversion of Phosphate Ester Prodrugs
Haodan Yuan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Disposition and Metabolism of a Novel Prostanoid Antiglaucoma Medication, Tafluprost, Following Ocular Administration to Rats
Y. Fukano et al.
DRUG METABOLISM AND DISPOSITION (2009)
Bimatoprost A Review of its Use in Open-Angle Glaucoma and Ocular Hypertension
Monique P. Curran
DRUGS & AGING (2009)
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Leonard W. Seymour et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor
Paul P. Dobesh
PHARMACOTHERAPY (2009)
Discovery and development of folic-acid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases
Philip S. Low et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Prodrug strategies in anticancer chemotherapy
Felix Kratz et al.
CHEMMEDCHEM (2008)
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
Joachim Stangier
CLINICAL PHARMACOKINETICS (2008)
Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Kristiina M. Huttunen et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol
Hanna Kumpulainen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome
Martin C. Michel
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Your prodrug releases formaldehyde: Should you be concerned? No!
Sundeep S. Dhareshwar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract
Qingyun Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Prodrugs for Amines
Ana L. Simplicio et al.
MOLECULES (2008)
Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs
Masakiyo Hosokawa
MOLECULES (2008)
Prodrugs: design and clinical applications
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist
Akio Nakamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S, 2S,5R,6S)-2-[(2′S)-(2-Amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs:: Assessment of first-pass bioactivation and dose linearity
Everett J. Perkins et al.
DRUG METABOLISM AND DISPOSITION (2007)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Prodrug strategies to overcome poor water solubility
Valentino J. Stella et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104
Adam V. Patterson et al.
CLINICAL CANCER RESEARCH (2007)
A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia
Steven P. Rivera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases
Scott A. Shaffer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
CYP2D6 Polymorphisms and the impact on tamoxifen therapy
Jacob N. Beverage et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel
Deshi Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis
Lucio Vera-Cabrera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives
Masahiro Tsuda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
M Karlgren et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Antitumor benzothiazoles. 26. 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines
CG Mortimer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers
A Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers
A Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Human carboxylesterase isozymes: Catalytic properties and rational drug design
Teruko Imai
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Fosamprenavir - Clinical pharmacokinetics and drug interactions of the amprenavir prodrug
MB Wire et al.
CLINICAL PHARMACOKINETICS (2006)
Polymer conjugates as anticancer nanomedicines
Ruth Duncan
NATURE REVIEWS CANCER (2006)
Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency
L Li et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Profiling cytochrome P450 expression in ovarian cancer:: Identification of prognostic markers
D Downie et al.
CLINICAL CANCER RESEARCH (2005)
Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist
AB Bueno et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR)
H Ebi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
Liver-targeted drug delivery using HepDirect1 prodrugs
MD Erion et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Gemtuzumab ozogamicin: A review of its use in acute myeloid leukaemia
C Fenton et al.
DRUGS (2005)
Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver
MD Erion et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers
S Sobue et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Enzyme-catalyzed activation of anticancer prodrugs
M Rooseboom et al.
PHARMACOLOGICAL REVIEWS (2004)
Transport of amino acid-based prodrugs by the Na+- and Cl- -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery
T Hatanaka et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir
ES Furfine et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:: I.: Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters
KC Cundy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:: II.: Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys
KC Cundy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Fluorinated 2-(4-amino-3-methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells
E Brantley et al.
DRUG METABOLISM AND DISPOSITION (2004)
A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
Lessons learned from marketed and investigational prodrugs
P Ettmayer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3
SP Sanghani et al.
DRUG METABOLISM AND DISPOSITION (2004)
Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist
K Beaumont et al.
CURRENT DRUG METABOLISM (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs
T Heimbach et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2003)
Identification of a human valacyclovirase - Biphenyl hydrolase-like protein as valacyclovir hydrolase
I Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
PDEPT:: Polymer-directed enzyme prodrug therapy.: 2.: HPMA copolymer-β-lactamase and HPMA copolymer-C-Dox as a model combination
R Satchi-Fainaro et al.
BIOCONJUGATE CHEMISTRY (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Absorption rate limit considerations for oral phosphate prodrugs
T Heimbach et al.
PHARMACEUTICAL RESEARCH (2003)
TAK-599, a novel N-phosphono type prodrug of Anti-MRSA cephalosporin T-91825:: Synthesis, physicochemical and pharmacological properties
T Ishikawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Effective drug delivery by PEGylated drug conjugates
RB Greenwald et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole
J Ohwada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
EK Rowinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Capecitabine - A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer
AJ Wagstaff et al.
DRUGS (2003)
Adefovir dipivoxil - A review of its use in chronic hepatitis B
TM Dando et al.
DRUGS (2003)
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives.: Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound
F Kratz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Pivalate-generating Prodrugs and carnitine homeostasis in man
EP Brass
PHARMACOLOGICAL REVIEWS (2002)
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
RJ Francis et al.
BRITISH JOURNAL OF CANCER (2002)
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers
C Falcoz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Structure-based design of novel potent nonpeptide thrombin inhibitors
NH Hauel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole
A Bentley et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2002)
Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of second generation prodrugs for targeted treatment of malignant melanoma
AM Jordana et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2001)
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA
C Ballatore et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Fosamprenavir -: Anti-HIV -: HIV protease inhibitor
LA Sorbera et al.
DRUGS OF THE FUTURE (2001)
Oseltamivir - A review of its use in influenza
K McClellan et al.
DRUGS (2001)
Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood
EJ Eisenberg et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2001)
Clinical pharmacokinetics of capecitabine
B Reigner et al.
CLINICAL PHARMACOKINETICS (2001)
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
NG Rainov
HUMAN GENE THERAPY (2000)
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine
N Shimma et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2000)
N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl] sulfonyl]propanamide, sodium salt, parecoxib sodium:: A potent and selective inhibitor of COX-2 for parenteral administration
JJ Talley et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs
JJ Hale et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
